Skip to main content
Skip to section navigation
Skip to footer
ViraxImmune™
Products
Services
Media
Leadership
Contact Us
Investor Relations
Menu
ViraxImmune™
Products
Services
Media
Leadership
Contact Us
Investor Relations
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
Board Diversity Matrix
All SEC Filings
Filing Type:
View All
20-F
424B3
424B4
424B5
6-K
8-A12B
CERT
CORRESP
D
DRS
DRS/A
DRSLTR
EFFECT
F-1
F-1/A
F-3
FWP
NT 20-F
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
Date
Form
Description
PDF
XBRL
Pages
03/10/22
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
5
02/17/22
DRSLTR
Correspondence Related to Draft Registration Statement
5
02/17/22
DRS/A
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
Documents
expand_more
EX-10.4
245
01/28/22
UPLOAD
SEC-generated letter
Documents
expand_more
TEXT-EXTRACT
8
12/27/21
DRS
Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
178
rss_feed
Filing RSS
Previous Page
arrow_back
Page
1
…
…
Page
2
Page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
Page
10
Page
11
Email Alerts
Contacts
RSS News Feed